ClinicalTrials.gg
TerminatedNCT01025869VANTAGE-1Updated Jan 12, 2016

The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries

An interventional study of Cinatra™ Corolimus Eluting Coronary Stent System in Coronary Artery Disease, sponsored by Atrium Medical Corporation. Terminated at 4 sites in New Zealand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-12.

Sponsored by Atrium Medical Corporation · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Terminated following completion of 2 year time point: Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Coronary Artery Disease with a site in New Zealand — 2 open to participants now, 7 under way, 1 of them phase 3. Coronary Artery Disease · New Zealand.

Enrollment
47th of 50
31 · median 398
Started
2009
with 6 others
No phase
21 of 52
none open now
Registered
21st of 52
by date
Lead sponsor
1 of 52
Atrium Medical Corporation

Among the 52 studies in Coronary Artery Disease with a site in New Zealand, this one is the 47th largest by enrollment of the 50 interventional ones that give a count, is one of 7 that started in 2009, is one of 21 with no phase, and was the 21st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 52 studies in Coronary Artery Disease with a site in New Zealand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in New Zealand have not opened yet or have stopped. Only those recruiting at a site in New Zealand →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Coronary Artery Disease with a site in New Zealand, or all of them as a file.
02

Study summary

To investigate the safety and efficacy of the Cinatra™ Corolimus Drug Eluting Stent for the treatment of de novo lesions in native coronary arteries.

Read the detailed description

This is a single-arm, multicentre pilot study designed to provide an indication of the effectiveness and safety of the Cinatra™ Corolimus Eluting Coronary Stent System. The primary endpoint to be evaluated in this study is late lumen loss (in-stent) at 6 months post-procedure as measured by QCA in the 30 participants undergoing angiography at this timepoint. Late lumen loss is defined as the difference between the post-index procedure minimal lumen diameter (MLD) and the follow-up MLD.

03

Conditions studied

  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is ≥ 18 years old
  2. Patient is an acceptable candidate for percutaneous coronary intervention (PCI), stenting, and emergent coronary artery bypass graft (CABG) surgery
  3. Patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, and/or a positive functional study
  4. Female subjects of must have a negative pregnancy test within 7 days before the trial procedure
  5. Patient or subject's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written as approved by the Hospital Research Ethics Committee (HREC) of the respective site
  6. Patient agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed

Angiographic:

  1. Patient has either a single target lesion, or two lesions (target and non-target) located in separate coronary arteries
  2. If a non-target lesion is treated, it must be treated first and only with commercially available PTCA balloons and/or stents. Post PCI of the non-target vessel, all of the following conditions must be met:

    • Residual diameter stenosis \<10%
    • Absence of any angiographic complications
    • Absence of ischaemic symptoms
    • Absence of significant new arrhythmia or monitoring changes suggestive of ischaemia
  3. Target lesion must be a de novo lesion in native coronary artery
  4. Target lesion must be ≤ 22 mm in length
  5. Target lesion must have a stenosis of ≥ 50% and \< 100%
  6. Target vessel must have a reference vessel diameter (RVD) appropriate for treatment with a of 3.0mm or3.5 mm stent
  7. Target vessel must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 2

Exclusion criteria

Exclusion Criteria:

  1. Known or to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, chromium, stent coatings (i.e. fatty acids, glycerides, and alpha tocopherol), or a sensitivity to contrast media, which cannot be adequately pre-medicated
  2. History of an allergic reaction or significant sensitivity to drugs such as , zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative
  3. count \< 100,000 cells/mm³ or > 700,000 cells/mm³, or a white blood cell (WBC) count \< 3,000 cells/mm³ within 7 days prior to index procedure
  4. Serum creatinine level 170 micromol/L within 7 days prior to index procedure
  5. Evidence of an acute myocardial infarction (MI) within 72 hours of the intended trial procedure (defined as: Q wave myocardial infarction (QWMI) or non-Q wave myocardial infarction (NQWMI) having CK enzymes > 2X the laboratory with the presence of an elevated CK-MB (any amount above the laboratory upper limit of normal)
  6. Previous PCI of the target vessel within 9 months prior to the procedure
  7. Any planned additional PCI procedure within 30 days post-index procedure and/or planned PCI of the target vessel within 12 months post-procedure
  8. During the index procedure, the target and/or non-target lesion(s) requires treatment with a device other than PTCA prior to stent placement (including, but not limited to, cutting balloon, atherectomy, thrombectomy, etc.)
  9. (LVEF) \< 30% if evaluated, or clinical evidence of significant congestive heart failure ( Class III or IV) within the prior 30 days
  10. History of a stroke or (TIA) within the prior 6 months
  11. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months
  12. History of bleeding diathesis or coagulopathy or will refuse blood transfusions
  13. Concurrent medical condition with a of less than 12 months
  14. Any previous treatment of the target vessel(s) for restenosis, including brachytherapy
  1. Any condition which, in the Investigator's opinion, may interfere with the subject's optimal participation in the study 17. Currently participating in an drug or another device trial that has not completed the primary endpoint or that clinically interferes with the current trial endpoints; or requires coronary angiography, IVUS or other coronary artery imaging procedures

Angiographic:

  1. Target lesion is located in native vessel distal to anastomosis with a saphenous vein graft or a left/right internal mammary artery (LIMA/RIMA) bypass with more than 40% diameter stenosis anywhere within the graft
  2. Previous stenting in the target vessel.
  3. The target vessel has other lesions with greater than 40% diameter stenosis based on visual estimate or on-line QCA
  4. The target vessel has evidence of thrombus
  5. The target vessel is excessively tortuous (two bends > 90º to reach the target lesion)
  6. The target lesion has any of the following characteristics:

    • Lesion location is aorto-ostial, an unprotected left main lesion, or within 5 mm of the origin of the left anterior descending (LAD) or left circumflex (LCX)
    • Involves a side branch > 2.0 mm in diameter
    • Is at or distal to a > 45º bend in the vessel
    • Is severely calcified
  7. Unprotected left main coronary artery disease (an obstruction greater than 50% in the left main coronary artery)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Other
    Stent System

    Cinatra™ Corolimus Eluting Coronary Stent System

    Device: Cinatra™ Corolimus Eluting Coronary Stent System

Interventions

  • DeviceCinatra™ Corolimus Eluting Coronary Stent System

    Stent implantation

06

What researchers measure

Primary outcomes

  1. In-stent late lumen loss (LLL) as measured by quantitative coronary angiography (QCA).

    Time frame: 6 months post treatment

Secondary outcomes

  1. Target lesion revascularization

    Time frame: 1, 6 and 18 month and annually to 5 years

  2. Target vessel revascularization

    Time frame: 1 month and at all follow up to 5 years

  3. Stent thrombosis

    Time frame: All follow ups

  4. Neointimal Hyperplasia

    Time frame: 6 and 18 months

  5. Binary restenosis

    Time frame: 6 and 18 months

  6. MACE (Major Adverse Cardiac Event)

    Time frame: 1 month, 6 month, 18 month and annually to 5 years

  7. In-segment late lumen loss (LLL) as measured by quantitative coronary angiography

    Time frame: 6 and 18 months

  8. In-stent late lumen loss (LLL) as measured by quantitative coronary angiography

    Time frame: 18 months (optional)

  9. Minimal Lumen Diameter (MLD), in-stent and in-segment

    Time frame: 6 and 18 months

  10. Rates of incomplete stent apposition

    Time frame: 6 and 18 months

  11. Device success defined as achievement of a final residual diameter stenosis of < 30% measured by QCA, using the study device only.

    Time frame: procedure

  12. Lesion treatment success is defined as <30% residual stenosis measured by QCA by any treatment

    Time frame: Procedure

  13. Procedure success defined as lesion success without the occurrence of MACE during the hospital stay

    Time frame: discharge

07

Study locations

4 sites
  • Auckland City Hospital
    Auckland, New Zealand
  • Mercy Angiography
    Auckland, New Zealand
  • North Shore Hospital
    Auckland, New Zealand
  • Christchurch Hospital
    Christchurch, New Zealand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Nov 2010 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2009
First posted
Dec 4, 2009
Start
Dec 2009
Primary completionActual
Nov 2010
CompletionActual
Mar 2012
Last update
Jan 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01025869
Lead sponsor
Atrium Medical Corporation
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Dec 2009
Primary completion
Nov 2010
Completion
Mar 2012
Last update
Jan 12, 2016

Study contacts

John Ormiston, MD
principal investigator · Associate Professor and Interventional Cardiologist at Auckland City Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion